Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Nears Astra AI Model Launch With Safety Focus 
OpenAI Rejects Apple Trade Secret Theft Claims 
Shein Shares Slide 9% in Hong Kong IPO Debut 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
NEW DELHI, India, March 12, 2018 -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announces that N. Venkat, chief executive officer and co-founder of Vyome Biosciences, will present at the Cowen and Company 38th Annual Health Care Conference at 11:30 a.m. EDT on Tuesday, March 13, 2018, at the Boston Marriott Copley Plaza, Boston.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic resistant acne being studied in phase 2 trials. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in and @VyomeBio.
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]
